Pending FDA approval: Cardinal Health to ready formulation for market

August 15, 2002

Irvine, CA-ISTA Pharmaceuticals and Cardinal Health will manufacture commercial quantities of Vitrase, a proprietary formulation of highly purified hyaluronidase, pending its FDA approval.